Synaptic Vesicle Glycoprotein 2C: a role in Parkinson's disease

Front Cell Neurosci. 2024 Sep 5:18:1437144. doi: 10.3389/fncel.2024.1437144. eCollection 2024.

Abstract

Synaptic Vesicle Glycoprotein 2C (SV2C), characterized by its selective expression in discrete brain regions such as the midbrain, has recently emerged as a promising player in Parkinson's Disease (PD) - a debilitating neurodegenerative disorder affecting millions worldwide. This review aims to consolidate our current understanding of SV2C's function, its involvement in PD pathogenesis, and to evaluate its potential as a therapeutic target. Integrating previous findings of SV2C, from genetics to molecular studies, and drawing on insights from the largest East Asian genome-wide association study that highlights SV2C as a novel risk factor for PD, we explore the potential pathways through which SV2C may influence the disease. Our discussion extends to the implications of SV2C's role in synaptic vesicle trafficking, neurotransmitter release, and α-synuclein homeostasis, thereby laying the groundwork for future investigations that could pave the way for novel therapeutic strategies in combating PD.

Keywords: Parkinson’s disease; Synaptic Vesicle Glycoprotein; dopamine; synaptic trafficking; synaptic vesicle.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work is supported by the Singapore Ministry of Health’s National Medical Research Council Open Fund Individual Research Grant (OF-IRG; MOH-000559), NMRC Open Fund—Large Collaborative Grant (OF-LCG; MOH-000207), the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE-T2EP30220–0005) and Tier 3 (MOE-MOET32020-0004).